TrialJournal of the European Academy of Dermatology and Venereology : JEADV2026

Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis.

Joseph F Merola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.